Together, these data provide preclinical validation of EphA2 as a clinically relevant molecular target for breast cancer bone metastatic disease, warranting further investigation of molecular mechanisms that link EphA2 to tumor‐induced osteolysis and potential development of a clinical inhibitor. Here, EPHA2 is linked to breast cancer.